SOMATOM Pro.Pulse Dual Source CT Scanner Cleared by FDA

Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the SOMATOM Pro.Pulse, a dual-source computed tomography scanner designed to be more affordable for a wide range of healthcare facilities, including outpatient diagnostic centers. The scanner combines the power and speed of dual-source CT technology—two X-ray tubes and two detectors—with embedded artificial intelligence and user assistance features to deliver workflow efficiencies.

Dual-source CT allows for high temporal resolution, which, along with scan speed, is important for cardiac CT scans to limit artifacts caused by breathing or cardiac motion. In recent years, interest in CT’s cardiovascular applications has increased in the U.S. This interest may be attributed in part to a 2021 decision by the American College of Cardiology (ACC) and the American Heart Association (AHA) to give cardiac CT angiography (CCTA) its highest recommendation as a frontline test to evaluate patients with stable and acute chest pain who have no history of coronary artery disease.^¹

The AI-powered intelligent user interface, myExam Companion, combines patient data (including gender, height, and age) and collects scan-relevant information such as heart rate or breath-hold capabilities to tailor a patient-specific scan protocol. The optional FAST (Fully Assisting Scanner Technologies) 3D camera automatically performs precise, consistent patient positioning.

The SOMATOM Pro.Pulse has an air-cooled gantry, requires 31 percent less space for installation than the company’s previous dual-source systems, and consumes 20 percent less power than traditional water-cooled dual-source CT scanners. These features reduce the scanner’s installation and operational costs compared to similar scanners in the company’s portfolio.

For more information, click here.

Contact for journalists

Jeff Bell

Phone:+484-868-8346; E-mail: jeffrey.t.bell@siemens-healthineers.com

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2023, which ended on September 30, 2023, Siemens Healthineers had approximately 71,000 employees worldwide and generated revenue of around €21.7 billion. Further information is available at https://www.siemens-healthineers.com/en-us.